With Pfizer’s COVID-19 vaccine approved and Moderna’s candidate on its heels, analysts are projecting major sales for the companies.
This week, Morgan Stanley released projections indicating that Pfizer could pull in $975 million in revenue for its coronavirus vaccine this year, and then another $19 billion in 2021. But even as the pandemic winds down and more competition enters the market, Pfizer’s vaccine is projected to remain a blockbuster with sales over $9 billion between 2022 and 2023.
Half of the revenue will go to BioNTech, the German company that co-developed the vaccine.
Moderna’s revenue are likely to be even more impressive when compared to its previous sales.
In 2019, Moderna, which has never had a drug product approved, pulled in just $60 million in sales. Now its COVID-19 vaccine could generate $10-15 billion in sales between 2021 and 2022, according to Morgan Stanley.
The FDA is expected to render an approval for Moderna’s candidate by the end of this week.
